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Na/H exchanger 3 (NHE3) plays a pivotal role in transepithe-
lial Na and HCO3 absorption across a wide range of epithelia in
the digestive and renal-genitourinary systems. Accumulating evi-
dence suggests that PDZ-based adaptor proteins play an important
role in regulating the trafficking and activity of NHE3. A search for
NHE3-binding modular proteins using yeast two-hybrid assays led
us to the PDZ-based adaptor Shank2. The interaction between
Shank2 and NHE3 was further confirmed by immunoprecipitation
and surface plasmon resonance studies. When expressed in PS120/
NHE3 cells, Shank2 increased the membrane expression and basal
activity of NHE3 and attenuated the cAMP-dependent inhibition of
NHE3 activity. Furthermore, knock-down of native Shank2 expres-
sion inCaco-2 epithelial cells by RNA interference decreasedNHE3
protein expression as well as activity but amplified the inhibitory
effect of cAMP on NHE3. These results indicate that Shank2 is a
novel NHE3 interacting protein that is involved in the fine regula-
tion of transepithelial salt and water transport through affecting
NHE3 expression and activity.
Maintenance of intracellular and systemic pH, Na concentration,
and fluid volume is essential for maintaining the physiological status in
cells andwhole organisms (1, 2). First demonstrated almost 30 years ago
(3), members of the mammalian Na/H exchanger (NHE)2 family
participate in the regulation of these parameters at both cellular and
systemic levels. To date, nineNHE familymembers have been identified
inmammalian cells with unique tissue distribution and functional prop-
erties (2). As a better characterized isoform, NHE3 is primarily found in
the apical membrane of epithelial cells of the renal and gastrointestinal
tracts, where it mediates transepithelial absorption of Na and HCO3
(2, 4). Lack of NHE3 activity impairs acid-base balance and extracellular
fluid volume homeostasis (5).
NHE3 is known to be regulated by a large variety of hormones, such as
- and -adrenergic agonists, dopamine, parathyroid hormone, and
angiotensin II via multiple signaling systems (6, 7), but the exact under-
lyingmechanisms are still only partially understood.Nevertheless, it has
been known for many years that acute regulation of NHE3 activity is
linked to protein phosphorylation, as in the case of inhibition by cAMP-
dependent protein kinase A (PKA) (7, 8). Subsequently, it has been
demonstrated that adaptor proteins with PDZ (PSD-95/discs large/
ZO-1) domains play an important role in the cAMP-dependent inhibi-
tion ofNHE3 in a number of systems (7, 9, 10). For example, EBP50 (also
known as NHERF1) and E3KARP (also known as NHERF2, SIP-1, or
TKA-1) were found to be necessary modular proteins that participated
in the cAMP-dependent PKA phosphorylation of NHE3 by forming a
multiprotein signaling complex (11, 12).
In recent years, there has been a growing interest in PDZdomains and
modular proteins having PDZ domains. Best studied in the post-synap-
tic density (PSD) region of neurons, PDZ domain proteins have
emerged as a large and important group of proteins that sequester func-
tionally related groups of receptor, regulatory, and effector proteins into
integratedmolecular complexes (13–15). Epithelial cells also utilize spe-
cific PDZ proteins to direct the polarized activities in their apical and
basolateral membranes. Recently, the PDZ-based scaffold protein
Shank2 has been shown to be distributed to the apical pole of pancreatic,
colonic, hepatic, and renal epithelia andmodulate the activity of specific
transport proteins, including cystic fibrosis transmembrane conduct-
ance regulator and the type IIa sodium phosphate cotransporter (16–
18). Shank proteins are a family of newly identified scaffold proteins
known to serve as a central coordinator of membrane protein com-
plexes in PSD (13, 14). Currently there are three knownmembers of the
Shank family: Shank1, Shank2, and Shank3. Among them,we found that
the PDZ domain of Shank2 binds to the carboxyl terminus of NHE3 in
an exploratory yeast two-hybrid assay. The present study aimed to iden-
tify and characterize the biochemical nature and physiological signifi-
cance of the association between Shank2 and NHE3 using integrative
molecular physiological approaches.
Upon Shank2 expression, the membrane expression and basal activ-
ity of NHE3 were increased but the cAMP-dependent inhibition of
NHE3 activity was attenuated in the PS120/NHE3 cells. Furthermore,
knock-down of native Shank2 expression by RNA interference evoked a
remarkable decrease in endogenous NHE3 activity in Caco-2 colonic
epithelial cells. Thus, Shank2 appears to be a critical regulatory protein
that affects NHE3 expression and activity.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—NHE-deficient hamster fibroblast
cells (PS120) were maintained in Dulbecco’s modified Eagle’s medi-
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um-HG (Invitrogen) supplemented with 10% fetal bovine serum and
penicillin (50 IU/ml)/streptomycin (50 g/ml). The pCMV-rNHE3
construct was a generous gift from Dr. K. Park at Juseong University,
Korea (19) and was stably transfected into a PS120 cell line using Lipo-
fectamine Plus Reagent (Invitrogen). NHE3 stable transfectants (PS120/
NHE3) were selected by resistance to antibiotic Geneticin (G418
Invitrogen) and by an H-killing method (20). The constructs of
pcDNA3.1-rShank2/CortBP1 (21) and pcDNA3.1-rShank2E (18) were
transiently transfected into PS120/NHE3 cells with or without
pcDNA3.1-EBP50/NHERF1 (9) using Lipofectamine Plus Reagent.
Caco-2 cells (human colon adenocarcinoma cells) were grown at 37 °C
in a 5% CO2-95% air environment. The culture medium consisted of
Dulbecco’s modified Eagle’s medium-HG, 10% fetal bovine serum, 50
IU/ml penicillin, and 50 g/ml streptomycin. Cells reached confluence
after 5–7 days in culture. They were used for experiments at least 7 days
after confluence, and the incubation medium was freshly changed on
alternate days.
Yeast Two-hybrid Analysis—The yeast two-hybrid assay was per-
formed as described earlier (22). The L40 yeast strain harboring the
reporter genes HIS3 and LacZ, under control of the upstream LexA
DNA-binding domainwas used in the assay. To semi-quantify the inter-
action,HIS3 activity was determined by the percentage of yeast colonies
growing on histidine-lacking medium. cDNA sequences containing the
carboxyl-terminal 32 aa of rNHE3 (aa 800–831: PFRLSNKSVDS-
FLQADGPEEQLQPASPESTHM) were amplified by PCR and sub-
cloned in-frame into pBHAconstruct (a bait vector containing the LexA
DNA-binding domain). The pGAD10 (a prey vector, Clontech) con-
structs containing the PDZ domains of SAP97, PSD-95, S-SCAM, and
Shank2 were previously described (16).
Surface Plasmon Resonance Measurements and Kinetic Analysis of
Sensorgrams—Regions corresponding to residues of Shank2 PDZ
(1–142) and of EBP50/NHERF1 PDZ1–2 (1–296) were PCR-amplified
and cloned into pRSET-A vector (Invitrogen) to create His-tagged con-
structs. Amino-terminal 32-aa residues of rNHE3 (NM_012654) were
PCR-amplified and cloned into pGEX-4T-1 vector (Amersham Bio-
sciences) to create glutathione S-transferase fusion constructs. All con-
structs were confirmed by sequence analysis. All fusion proteins were
expressed in Escherichia coli BL21(DE3) cells and purified on nickel-
nitrilotriacetic acid resin (Qiagen, Venlo,Netherlands) and glutathione-
Sepharose 4B (Amersham Biosciences), as appropriate. The purified
proteins were quantified with Bio-Rad protein assay reagent, and their
purity was assessed as90% by Coomassie Blue staining of SDS-PAGE
gels.
A surface plasmon resonance system equipped with nitrilotriacetic
acid chip (BIAcore 3000, BiacoreAB, Uppsala, Sweden) was used for the
capturing of His-tagged PDZ fusion proteins. Analytes (glutathione
S-transferase-tagged C-terminal 32 aa of rNHE3) at various concentra-
tions in HEPES-buffered saline-EP (0.01 M Hepes, 0.15 M NaCl, 50 M
EDTA, 0.005% Tween 20, pH 7.4) were perfused at a flow rate of 30
l/min. The sensor chip was regenerated between each analysis using
successive injections of solutions containing 0.15 M NaCl and 0.35 M
EDTA. At least two replicate experiments were performed for each
fusion protein. Response curves were generated by subtraction of the
background signal generated simultaneously by the control flow cell.
The background-subtracted curves were prepared for fitting by sub-
tracting the signal generated by buffer alone on experimental flow cells.
Sensorgram curves were evaluated by the BIAEVALUATION 3.0 soft-
ware (Biacore AB), which uses numerical integration algorithms.
Immunoblotting and Immunoprecipitation—PS120 or Caco-2 cell
lysates (2 mg of protein) were mixed with the appropriate antibodies
and incubated overnight at 4 °C in lysis buffer. Immune complexes were
collected by binding to protein G/A-Sepharose and washed four times
with lysis buffer prior to electrophoresis. The immunoprecipitates or
lysates (50 g of protein) were suspended in SDS sample buffer and
separated by SDS-polyacrylamide gel electrophoresis. The separated
proteins were transferred to nitrocellulose membranes, and the mem-
branes were blocked by a 1-h incubation at room temperature in 5%
nonfat dry milk in a solution containing 20 mM Tris-HCl, pH 7.5, 150
mM NaCl, and 0.05% Tween 20. The membranes were then incubated
with the appropriate primary and secondary antibodies, and protein
bandswere detectedwith enhanced chemiluminescence solutions. Rab-
bit polyclonal 1568 antisera againstNHE3 (23) and 1136 antisera against
Shank2 (20) were described previously. Mouse monoclonal antibody
against the carboxyl terminus of human -actin was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal antibod-
ies against NHE1 and NHE2 were from Dr. S. Grinstein, Hospital for
Sick Children, Toronto, Canada and Dr. E. Chang, University of Chi-
cago, IL, respectively, and the specificity of each antibodywas verified in
previous reports (24–26).
Cell-surface Biotinylation Assay—PS120/NHE3 and PS120/NHE3/
rShank2 cells were grown to 70–80% confluence in 6-cm Petri dishes.
The cells were then placed at 4 °C and then washed twice in phosphate-
buffered saline and once in borate buffer (in mM: 154 NaCl, 10 boric
acid, 7.2 KCl, 1.8 CaCl2, pH 9.0). The plasma membrane proteins were
then biotinylated by gently shaking the cells in a borate buffer contain-
ing sulfo-NHS-SS-biotin (Pierce) for 30 min. After biotinylation, the
cells were washed extensively with quenching buffer to remove excess
biotin and then washed twice with phosphate-buffered saline. The cells
were then lysed, and NeutrAvidin solution (UltraLink Immobilized
NeutrAvidin Beads 10%, Pierce) was added to the supernatant and the
mixturewas incubated at 4 °C overnight. Avidin-bound complexeswere
pelleted (13,000 rpm) and washed three times. Biotinylated proteins
were eluted in Laemmli buffer, resolved by SDS-PAGE, electrotrans-
ferred, and immunoblotted with NHE3 antibody.
Genome Screening, Reverse Transcription-PCR, and cDNA
Sequencing—To identify the epithelial splice variant of human Shank2
(hShank2E), the 400,000 bp upstream of the start codon of hShank2 (a
homologous protein of rCortBP1, accession number NM_012309) on
human chromosome 11was analyzed using the rat Shank2E sequence as
a reference sequence (rShank2E, accession number AY298755). Puta-
tive exons were determined by the New GENSCAN web server at the
Massachusetts Institute of Technology. A list of candidate exons were
chosen with 5 scoring, translated into protein sequence, and aligned
with that of rShank2E. During this process, non-homologous exons
were excluded. A human EST AK096045 was also used for the analysis
of the hShank2E sequence. To confirm the hShank2E sequence, PCR
primers specific to hShank2E, especially to the ankyrin repeats domain
were designed and cDNAproducts were sequenced using anABI-Prism
sequencer. Reverse transcription-PCR using a primer set from exons 1
and 17 produced a 2,122-bp band, and the whole DNA sequence of this
product was submitted to the GenBankTM data base with accession
number DQ152234 (see Fig. 5). hShank2E cDNA sequence from exons
1–8 was identical to that of a partial EST clone isolated from human
kidney (AK096045) except exon 2, where an internal alternative splicing
is evident in the EST clone.We could not find sequences corresponding
to exon 8 on the human genome contig of chromosome 11
(NT_033927), although our sequence perfectlymatchedwith that of the
EST (AK096045) clone. It could be either from short repeated exons in
the region or erroneous information in the genome contig. In addition,
a PCR primer set that can specifically detect hShank2/CortBP1 was
Shank2 Regulates NHE3
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designed to confirm the presence of this splicing variant in Caco-2 epi-
thelial cells. The primer sequences were as follows: 1) hShank2E, sense
(exon 1, 5-ATGCCGCGCAGCCCAACATC-3); 2) hShank2/
CortBP1, sense (exon 15a, 5-CGCTGTCCCCGGAATTCTCTCT-3);
and 3) hShank2 common, antisense (exon 17, 5-CCTGCCGGAT-
CATGTTCACCAC-3). The sizes of the hShank2E and hShank2/
CortBP1 PCRproductswere 2,122 and 295 bp, respectively (see Fig. 5C).
The control -actin primer sequences were as follows: h-actin, sense
(5-TGTGATGGTGGGAATGGGTCAG-3) and antisense (5-TTT-
GATGTCACGCACGATTTCC-3); size of PCR product, 510 bp.
RNA Interference—To knock down Shank2 expression in Caco-2 epi-
thelial cells, 25-bp double-stranded RNA oligonucleotides, specific for
Shank2, were synthesized (Invitrogen) and transfected into cells using
Lipofectamine 2000 (Invitrogen). The target small interfering RNA
(siRNA) sequence was as follows: 5-GGAATTCTCTCTACAGT-
GACTGCAT-3. Four days after transfection, cells were used for NHE
measurements or harvested in lysis buffer for immunoblotting.
Measurement of Na/H Exchange Activity—Na/H exchange
activity was measured using a standard protocol with some modifica-
tions (9). Briefly, cells grown on glass coverslips were loaded with a
pH-sensitive fluorescent dye 2,7-bis-(2-carboxyethyl)-5-(and-6)-car-
boxyfluorescein acetoxymethyl ester and intracellular pH (pHi) changes
were measured. When Shank2 constructs were transiently expressed
(Figs. 2 and 3), a green fluorescent protein-expressing plasmid (Invitro-
gen) was co-transfected and pHi measurements were performed with
cells expressing high levels of green fluorescent protein as previously
reported (27). The cells were acidified by an NH4 (20 mM) pulse and
subsequent perfusionwith anNa-free solution. Themaximal Na-de-
pendent pHi recoverywasmeasured in cells acidified to a pHof 6.4–6.5,
with or without 5 M forskolin/100 M isobutylmethylxanthine treat-
ment. The standard perfusion solution contained (mM): 140 NaCl, 5
KCl, 1 MgCl2, 1 CaCl2, 10 glucose, and 10 Hepes (pH 7.4 with NaOH).
Na-free solutions were prepared by replacing Na with N-methyl-D-
glucamine. The osmolarity of all solutions was adjusted to 310 mM
with the major salt. Buffer capacity was calculated by measuring pHi in
response to 5–20 mM NH4Cl pulses. In each experiment, the intrinsic
buffer capacity (i) showed a negative linear relationship with pHi
between 6.4 and 7.3. The i of PS120/NHE3 cells (34.1 3.9 mMNH4/
pH unit at pHi 7.0) was lower than that of Caco-2 cells (44.4  3.5).
However, neither forskolin treatment nor any gene modulation signifi-
cantly changed i. Therefore, all of the results of NHE activity are
expressed as pH/min, and this value was directly analyzed without
compensating for i. The results are presented as means  S.E., and,
when appropriate, statistical analysis was performed using Student’s t
test or analysis of variance. A p value less than 0.05 was considered
statistically significant.
RESULTS
Specific Binding between Shank2 PDZ and the Carboxyl Terminus of
NHE3—It has been repeatedly reported that the carboxyl terminus of
NHE3 plays an important role in both surface expression and regulation
of the activity of NHE3 through interactions with the PDZ-domain of
NHERF family proteins (7, 10). In a previous study (16) and in prelimi-
nary experiments for the present study, we observed that pancreatic and
colonic epithelia express several PDZ-based adaptor proteins in addi-
tion to NHERF family proteins using reverse transcription-PCR. These
include SAP97, PSD-95, S-SCAM, and Shank2 proteins. Therefore, we
hypothesized that the carboxyl terminus of NHE3 may associate with
other PDZ-based adaptors in epithelia. To explore the possible protein-
protein interactions between the carboxyl terminus of NHE3 and the
PDZ domains of these adaptor proteins, we performed a semi-quanti-
tative yeast two-hybrid assay. As presented in supplementary Table S1,
FIGURE 1. Protein-protein interaction between
Shank2 and NHE3. A, immunoprecipitation.
Whole cell lysates of PS120/NHE3 cells transiently
transfected with pcDNA3.1-rShank2/CortBP1 or
mock plasmids were immunoprecipitated with
Shank2 antibody and characterized by immuno-
blotting with NHE3 antibody. B, surface plasmon
resonance (SPR) assay. His-tagged Shank2 PDZ
domain was captured with an nitrilotriacetic acid
chip, and various concentrations of peptides con-
taining the C-terminal 32 aa of NHE3 were per-
fused at a flow rate of 30 l/min. Association and
dissociation constants shown are an average of
two separate experiments.
Shank2 Regulates NHE3
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the PDZ domain of Shank2 showed a potent induction of bothHIS3 and
-galactosidase reporter genes in yeast, indicating a direct protein-pro-
tein interaction between the carboxyl terminus of NHE3 and the PDZ-
domain of Shank2.
To verify the interaction between NHE3 and Shank2 in mammalian
cells, PS120 cells stably expressing NHE3 (PS120/NHE3) were tran-
siently transfected with pcDNA3.1-rShank2/CortBP1 or with mock
plasmids, and immunoprecipitation experiments were performed. As
shown in Fig. 1A, transfection of pcDNA3.1-rShank2 induced the
expression of Shank2 protein with a molecular mass of about 165 kDa
(arrowhead). Notably, a prominent NHE3 signal was always detected in
the Shank2 immunocomplexes precipitated from rShank2-transfected
cells in a total of three experiments.
The binding kinetics between the Shank2 PDZ domain and the car-
boxyl terminus of NHE3 were analyzed by surface plasmon resonance
experiments. As depicted in Fig. 1B, Shank2 PDZ domain captured in
nitrilotriacetic acid chips specifically binds to the carboxyl terminal 32
aa of NHE3, and its overall dissociation constant at equilibrium status
(KD) was calculated as 1.2	 107 M, which was within a range similar to
that of interaction between the carboxyl terminus of NHE3 and EBP50/
NHERF1 (1.5	 107 M, figure not shown).
Functional Interaction between Shank2 and NHE3 in PS120 Cells—
To investigate the functional significance of Shank2 binding on
NHE3 activity, the impact of Shank2 on the surface distribution and
activity of NHE3 was measured. In PS120 cells that stably express
NHE3, the total amount of NHE3 protein and surface-expressed
proteins were compared by using immunoblotting of total cell
lysates and surface biotinylated proteins, respectively, in cells trans-
fected with pcDNA3.1-rShank2 or with mock plasmids (Fig. 2A).
The total amount of NHE3 protein was not different in the two
groups. In contrast, cell-surface expression of NHE3 was increased
2.2  0.4 times in cells transiently expressing Shank2.
NHE3 activity is primarily regulated by the surface expression of
NHE3 molecules. The above results imply that by modulating the sur-
face distribution of NHE3, Shank2 might regulate the activity of NHE3
(2, 28). To test this directly, NHE activity in PS120/NHE3 cells was
measured in cells concurrently expressing Shank2. NHE activity was
measured as theNa-dependent increase in pHi after intracellular acid-
ification induced by an NH4 pulse as detailed under “Experimental
Procedures.”Most studiesmeasuringNHE3 kinetics in PS120 cells have
been done under serum-deprived conditions, because serum depriva-
tion for 18 h increases NHE3 activity and expression (9). However, the
initial set of NHE3 measurements in the present study was done under
serum-supplemented conditions, because the induction of NHE3
expression by serum deprivation would deter the innate regulation of
NHE3 in PS120 cells and also because immunoblotting and surface
biotinylation results shown in Fig. 2A were performed under serum-
supplemented conditions. In fact, we observed that serum deprivation
blunted the Shank2-induced increase in NHE3 surface expression (data
not shown). Traces of NHE activity measurements are shown in Fig. 2
(C andD), and a summary of results is illustrated in Fig. 2B. Notably, the
basal NHE activity was increased 1.8  0.3-fold upon Shank2 expres-
FIGURE 2. Effects of Shank2 expression on NHE3 in PS120/NHE3 cells. A, whole cell lysates and surface biotinylated proteins from PS120/NHE3 cells transiently transfected with
pcDNA3.1-rShank2/CortBP1 or mock plasmids were immunoblotted with NHE3 antibody. Three separate experiments showed similar results. B–D, basal and cAMP-stimulated
(forskolin (5M) plus isobutylmethylxanthine (100M)) NHE activities weremeasured in PS120/NHE3 cells kept in serum-supplemented conditions. Representative traces from cells
transfected with mock plasmids and pcDNA3.1-rShank2/CortBP1 are shown in C and D, respectively, and a summary of multiple experiments (n 7 for each) is depicted in panel B.
*, p
 0.05.
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sion, which correlates with the results of NHE3 surface biotinylation. In
a previous study, we found that cAMP-dependent inhibitory regulation
of NHE3 was partially retained in PS120 cells, in particular, when the
cells were kept in serum-supplemented conditions due to a minimal
endogenous expression of EBP50/NHERF1 (9). Therefore, NHE activity
was measured under basal and cAMP-stimulated conditions.When the
cells were treated with the cAMPmixture (forskolin 5 M plus 3-isobu-
tyl-1-methylxanthine, 100M), NHE activity was decreased by 21 5%
in control PS120/NHE3 cells and showed a statistically significant dif-
ference from the basal activity (p 0.011). Interestingly, Shank2 expres-
sion attenuated the cAMP-dependent inhibition. In PS120/NHE3 cells
transiently transfected with Shank2, cAMP treatment inhibited NHE
activity by only 7 5%, a significantly smaller reduction inNHE activity
compared with control PS120/NHE3 cells (p 0.451).
cAMP-mediated regulation of NHE3 within renal and intestinal epi-
thelia is important in maintaining systemic pH and electrolyte homeo-
stasis (2, 7). Therefore, the effects of Shank2 on cAMP-dependent inhi-
bition of NHE3 were further examined using a more sophisticated
system (Fig. 3). In this set of experiments, EBP50/NHERF1 was co-
expressed to maximally enhance the cAMP-mediated inhibition, and
serum was omitted from culture media for 18 h to increase basal NHE3
activity as well as to minimize the Shank2-induced increase in basal
activity. In addition, experiments studying the effects of Shank2E, a
splicing variant of Shank2 that is principally found in epithelial tissues
(17), were also included. cAMP treatment decreased NHE3 activity by
41 5% in EBP50/NHERF1-expressing cells.When Shank2 or Shank2E
was co-expressed, cAMP-dependent inhibition of NHE3 activity was
remarkably attenuated (Fig. 3B). Although Shank2E has additional pro-
tein domains besides those present in Shank2 (see Fig. 5A), there was no
significant difference in their ability to attenuate cAMP-dependent
inhibition of NHE3 in PS120 cells.
Expression of Shank2 and NHE3 in Caco-2 Colonic Epithelial Cells—
To identify the physiological significance of Shank2-NHE3 interaction,
it is necessary to examine the effects of endogenous Shank2 on native
NHE3 activity in epithelial cells. Caco-2 cells originated from human
colonic epithelia are known to express NHE3, and the benefits of using
Caco-2 cell clones as an in vitro model for studies on physiology of
NHE3 have been reported (29). We screened Caco-2 cells from two
different sources, the American Type Culture Collection (ATCC, HTB-
37) and the Korea Cell Line Bank (KCLB, 30037). Because the cells from
KCLB showed greater Shank2 expression (see below), we used this
batch of cells for further experiments. In pilot studies, NHE3 expression
was not detected in Caco-2 cells harvested at post-confluent day (PCD)
0 and 2 (Fig. 4). In contrast, PCD 5 cells expressed NHE3 and NHE3
protein level was the greatest at PCD 7. Consistent with protein expres-
sion levels, NHE3 activity was detected in cells at PCD 7 but not PCD 0
(Fig. 4, B and C). This gradual development of the NHE3 expression is
similar to other proteins expressed at the brush border of Caco-2 cells
such as sucrase-isomaltase, lactase, and alkaline phosphatase (30).
Based on these results, all the subsequent Caco-2 experiments were
done on or after PCD 7.
Expression of Shank2 was also identified in Caco-2 cells. It has been
demonstrated that rat epithelial cells expressed rShank2E, a different
spliceoform of rShank2/CortBP1 and ProSAP1A that had been identi-
FIGURE 3. Effects of Shank2 on cAMP-dependent inhibition of NHE3. Basal and cAMP-stimulated NHE activities were measured in PS120/NHE3 cells transfected with mock
plasmids, pcDNA3.1-rShank2/CortBP1, or pcDNA3.1-rShank2E. To observe a strong basal activity and a large cAMP-induced inhibition, PS120/NHE3 cells were deprived of serum for
18 h and co-transfected with EBP50/NHERF1-expressing plasmids. Representative traces from cells transfected with mock plasmids and pcDNA3.1-rShank2E are shown in C and D,
respectively. Summaries of NHE activity andpercentile inhibition of NHE activity by cAMP treatment (Control n 7, rShank2 n 8, rShank2E n 9) are shown inA and B, respectively.
**, p
 0.01.
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FIGURE 5. Expression of Shank2 proteins in Caco-2 cells. A, domain compositions of rat Shank2 splicing variants. B, exon structures of human Shank2 splicing variants isolated in
Caco-2 cells. Existence of exon 9 was observed in a partial EST clone (AK096045). C, PCR reactions on cDNA prepared from Caco-2 cells revealed that Caco-2 cells express mRNAs of
both hShank2E and hShank2/CortBP1 isoforms. Primer locations for each Shank2 isoform are presented in panel B. D, endogenous expression of Shank2 protein was verified in two
different batches (ATCC, HTB-37; KCLB, 30037) of Caco-2 cells by blotting with Shank2 antibody. Protein sample of control lane (left-hand lane) was prepared from PS120/NHE3 cells
transfected with rShank2/CortBP1.
FIGURE 4. NHE3 expression in Caco-2 cells. A,
NHE3 expression was verified in Caco-2 cells
(KCLB, 30037) collected on post-confluent days
(PCD) 0, 2, 5, 7, and 10 by immunoblotting with
NHE3 antibody. B and C, NHE3 activities were
measured in Caco-2 cells after treatmentwith EIPA
5 M to inhibit NHE1 and NHE2 isoforms. Cells on
PCD 7 showed a 5 M EIPA-resistant NHE activity
(C), while cells on PCD 0 showed no identifiable 5
M EIPA-resistant NHE activities (B). Cells using a
different batch of Caco-2 cells (ATCC, HTB-37)
showed similar results.
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fied in rat brain (17) (Fig. 5A). Therefore, we attempted to investigate
the human homologues of these isoforms as detailed under “Experi-
mental Procedures.” PCR reactions usingmultiple primer sets on cDNA
prepared from Caco-2 cells revealed that Caco-2 cells express at least
two different isoforms, hShank2/CortBP1 and hShank2E. hShank2E
was a homologue of rShank2E, and the N-terminal coding sequence of
its mRNA had 13 additional exons not present in the hShank2 mRNA
(accession number DQ152234, Fig. 5B). Reverse transcription-PCR
using a primer set from exons 1 and 17 produced a 2122-bp band spe-
cific to hShank2E (Fig. 5, B andC). The open reading frame of hShank2/
CortBP1 starts 89 bp upstream of exon 15 (exon 15a), and its sequence
was identical to that of the previously identified hShank2 in human
brain (NM_012309). Reverse transcription-PCRusing a primer set from
exons 15a and 17 produced an expected 295-bp band of hShank2 in
Caco-2 cells (Fig. 5, B and C). Finally, expression of both hShank2E and
hShank2 in Caco-2 cells was demonstrated by immunoblotting. We
tested two batches of Caco-2 cells from ATCC and KCLB. Basically,
they showed identical band patterns, a 165-kDa band corresponding to
hShank2/CortBP1 and a 240-kDa band corresponding to hShank2E,
although the batch from KCLB expressed slightly more of both Shank2
proteins (Fig. 5D). When analyzing band intensities, it was found that
the amount of Shank2E protein was 1.8  0.2-fold higher than that of
Shank2/CortBP1 in Caco-2 cells.
Effect of Shank2Knock-down onNHE3 inCaco-2 Epithelial Cells—To
determine whether Shank2 has any physiologically relevant effects on
NHE3, RNA interferencewas used to knock down Shank2 expression in
Caco-2 cells. We designed several sets of siRNAs, and one of these,
which acted on exon 15a, showed a good effect in inhibiting Shank2
expression. This siRNA on exon 15a was designed to break down RNAs
of hShank2. However, 12 nucleotides at its 3-end (sense strand) were
perfectly matched with the beginning region of exon 15 of Shank2E and
also inhibited hShank2E expression. This could be due to an inhibition
of translation observed in small RNAs that matched to the 3 region of
target mRNA (5 region of the antisense strand of siRNA) (31). Trans-
fection of siRNA in Caco-2 cells decreased protein expression of
hShank2 and hShank2E by 89 4% and 76 8%, respectively (Fig. 6A,
left panel). Importantly, knock-down of Shank2 was paralleled by a loss
ofNHE3 protein (52 8%) comparedwith control cells (Fig. 6A,middle
panel). Treatment of siRNA has been noted for the knock-down of
non-related genes. However, the persistent expression of a nonspecific
band detected by anti-Shank2 1136 antibody when treated with Shank2
siRNA (Fig. 6A, left panel, band A) suggests that the siRNA used is
specific for Shank2 RNAs. In addition, the expression levels of -actin,
NHE1, and NHE2 were not affected by Shank2 siRNA treatment (Fig.
6A, right panel).
Lastly, the effects of Shank2 loss on NHE3 activity were investigated
in Caco-2 cells. NHE3 activity was measured using protocols similar to
those used in PS120/NHE3 cells, except that 5M5-(N-ethyl-N-isopro-
pyl) amiloride (EIPA) was added to inhibit NHE1 and NHE2 that
expressed in Caco-2 cells (32). Individual traces of NHE activity meas-
urement are shown in Fig. 6 (C andD), and summaries of the results are
illustrated in Fig. 6B. In agreement with the findings from immunoblot-
FIGURE 6. Effect of Shank2 loss on NHE3 in Caco-2 cells. A, equal amounts (50 g) of protein samples from Caco-2 cells (KCLB, 30037) treated with mock or Shank2 siRNA were
immunoblotted against Shank2 antibody (left panel), NHE3 antibody (middle panel), and-actin, NHE1 andNHE2 antibodies (right panel). B–D, basal and cAMP-stimulated (Forskolin
(5 M) plus isobutylmethylxanthine (100 M)) NHE3 activities were measured in Caco-2 cells treated with mock or Shank2 siRNAs. Representative traces are shown in C and D, and
summaries of multiple experiments (Control n 6, Shank2 siRNA n 5) are presented in B. *, p
 0.05.
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ting, basal NHE3 activity was reduced upon Shank2 loss. Moreover, the
cAMP response of inhibiting NHE3 was increased in the Shank2
siRNA-treated cells, and this result exactlymatched the cAMP response
observed in the heterologous expression system of PS120/NHE3 cells
(Fig. 3). Therefore, it was concluded that Shank2 affects cAMP signaling
on NHE3 activity as well as NHE3 expression in Caco-2 epithelia.
DISCUSSION
Sequestering specific membrane proteins into apical and basolateral
compartments is critical for development, maintenance, and regulated
function of polarized epithelia. PDZ-based molecular adaptors have
emerged as key organizers of epithelial microdomain structures that
govern epithelial polarity and vectorial transport (33, 34). In the present
study, we report a novel protein-protein interaction between the PDZ-
based scaffold Shank2 and an epithelial transporterNHE3, which affects
membrane expression and cAMP-dependent regulation of the
transporter.
NHE3 is one of five plasma membrane Na/H exchangers and is
encoded by SLC9A3 in humans. It is expressed on the apicalmembranes
of renal proximal tubule and intestinal epithelial cells. Lack of theNHE3
activity impairs acid-base balance and systemic fluid volume homeosta-
sis (5).Many hormones, neurotransmitters, and the associated signaling
systems such as cAMP, cGMP, and elevated intracellular calcium have
been identified as regulators of NHE3 in various tissues and cell lines.
One well studied system is the cAMP-PKA-mediated pathway (2, 7).
Down-regulation of NHE3 activity by cAMP-PKA pathways involves
phosphorylation of carboxyl-terminal serine residues of NHE3 in vitro
and in vivo (8), and this inhibition only occurs in the presence of the
PDZ-based modular adaptors, NHERF1/EBP50 or NHERF2/E3KARP,
which link NHE3 to Ezrin, a low affinity PKA-anchoring protein (10). It
has been shown that cAMP-PKA pathways decrease both the mem-
brane expression of NHE3molecules and the turnover rate of the trans-
porter, although there have been considerable degrees of heterogeneity
among the stimulating agonists and the cell types (6, 35).
In line with the regulatory mechanisms of NHE3, the present study
reports two remarkable findings regarding the PDZ-containing modu-
lar protein Shank2: 1) Shank2 blunted the cAMP-dependent acute inhi-
bition of NHE3, and 2) Shank2 increased surface expression of NHE3.
The cAMP-dependent acute inhibition can be due to a change in pHi
sensitivity or Vmax of the transporter (35) or even due to an acute
decrease in surface expression (6). Although the mechanisms by which
cAMP signals acutely inhibit NHE3 are diverse, protein phosphoryla-
tion by PKA type II has been demonstrated to be an essential common
event (6, 8, 37). Based on the data from this study, it can be speculated
that Shank2 binding can blunt the effect of cAMP-PKA either by chang-
ing the phosphorylation status of NHE3 independent of the
EBP50ezrinPKA complex or by competing with the PDZ-based scaf-
folds associated with PKA-anchoring protein, thus breaching the for-
mation of protein complexes that would lead to PKA-dependent phos-
phorylation. It is interesting to note that the PDZ domains of Shank
proteins have a very similar three-dimensional structure to that of the
PDZ1 domain of EBP50/NHERF1 (36). In particular, they contain a
negatively charged amino acid at the end of the C strand of the PDZ
domain structures (Glu43 in hEBP50, Asp634 in rShank1, and Asp80 in
hShank2), which serves the preference for a positively charged residue
at the 1 position in the carboxyl terminus of membrane transporter,
such as -TRL in cystic fibrosis transmembrane conductance regulator
and -THM in NHE3 (36). Therefore, it is possible that Shank2 might
compete against EBP50/NHERF1 in their PDZ-ligand binding in cells
expressing both adaptor proteins. Further studies on the effects of
Shank2 expression on phosphorylation of NHE3 or on the possible
competition for binding between Shank2 and other epithelial PDZ-
based adaptors will be needed to address these questions.
In addition to the modulation of cAMP effects, Shank2 induced an
increase in surface expression of NHE3. An effective and rapid way of
controlling the function of cell-surface proteins is by altering the num-
ber of available molecules at the plasmamembrane. Studies on the sub-
cellular localization of NHE3 revealed the existence of a substantial
intracellular pool of transporters in vesicles as well as at the membrane
surface, indicating that NHE3 traffics between the plasma membrane
and recycling endosomal vesicles under basal and regulated conditions
(38). There could bemany explanations for the increased surface level of
NHE3 by Shank2, because Shank family proteins are known to be
engaged in the sorting, targeting, and organizing of target proteins (13,
15). As amaster scaffold, Shank holds together theN-methyl-D-aspartic
acid receptor, metabotropic glutamate receptor and AMPA receptor
complexes and promotes synaptic accumulation of PIX and PIX-
associated signalingmolecules at the PSD of excitatory synapses (21). In
addition, it was found that Shank2 interacts with Dynamin, a GTPase
involved in synaptic vesicle recycling, receptor-mediated endocytosis,
and other types of membrane trafficking (39). This observation further
supports the possibility that Shank2 is involved in the trafficking of
NHE3 and promotes stable membrane expression of the transporter.
An unexpected finding in this study was the decreased NHE3 protein
level following loss of Shank2 in Caco-2 cells. It should be noted that the
heterologous expression system of PS120/NHE3 cells may lack some
important factors specific to epithelial cells. Thus, Caco-2 cells were
used as a native epithelial cell system to investigate physiological effects
of Shank2 on NHE3 activity. Caco-2 cells, which natively express both
Shank2 and NHE3, are a colon cancer cell line that have been used to
model a number of absorptive functions of intestinal epithelial cells (29,
30). Importantly, Shank2 expression induced an increase in the total
amount of NHE3 protein in Caco-2 epithelial cells. However, in the
heterologous expression system of PS120/NHE3 cells, Shank2 induced
an increase only in the level of surface NHE3 protein. The most plausi-
ble explanation for this difference is that the increased membrane sta-
bility of NHE3 by Shank2 can evoke an observable increase in the total
amount of NHE3 in Caco-2 cells, where NHE3 expression is controlled
by an innate promoter system, but not in PS120/NHE3 cells, where a
large amount of NHE3 is produced by uncontrolled CMV promoters
and a larger intracellular pool of NHE3 may exist. However, an alterna-
tive possibility is that Shank2 may affect the transcription of NHE3.
There have been many reports suggesting the involvement of PDZ-
containing proteins in the transcriptional regulation of target proteins.
For example, EBP50/NHERF1 has been reported to interact with
-catenin through its carboxyl-PDZ domain and enhance -catenin-
dependent transcription in a dose-dependentmanner (40). Recent stud-
ies have also reported a transcriptional coactivator TAZ with PDZ-
binding motif that has been shown to interact with E3KARP/NHERF2
and to be involved in gene regulation (41). The underlying mechanisms
responsible for the decreased NHE3 proteins on Shank2 loss in Caco-2
cells are currently under investigation.
Shank/CortBP/ProSAP family of PDZ-based adaptor proteins were
identified independently by several investigators and suggested to be an
important organizer in the postsynaptic specialization of neuronal cells
(13). In epithelial cells, Shank2 isoforms (CortBP1, ProSAP1A, and
Shank2E) are highly expressed in the apical pole of epithelia (16–18).
Shank proteins contain multiple protein-protein interaction sites,
including ankyrin repeats, an SH3 domain, a PDZ domain, a long pro-
line-rich domain, and a SAMdomain. Shank2E has all five protein inter-
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action sites, whereas Shank2/CortBP1 has only the last three. In the
present study, we found that both Shank2/CortBP1 and Shank2E are
co-expressed in Caco-2 epithelia at an approximate 2:1 ratio. Interest-
ingly, functional assays found no differences in the regulation of NHE2
by Shank2/CortBP1 and Shank2E. This does not mean that the two
different isoforms play the same role in epithelia. Identifying the binding
partners of Shank2E-specific sites in epithelia and the differential
knock-out of the splicing variants will be needed to understand the
specific role of each isoform.
The physiological relevance of Shank2-NHE3 interaction can be
appreciated from several points. Firstly, Shank2 up-regulates surface
expression of NHE3 and the basal activity of NHE3 in epithelial cells.
Considering the fact that NHE3 is a major transporter in the electro-
neutral uptake of NaCl in intestinal epithelia and in the reabsorption of
NaHCO3 and NaCl in the renal proximal tubule, maintaining basal
NHE3 activity is important in fluid volume, electrolyte, and acid-base
homeostasis. Secondly, the inhibition of cAMP-dependent signaling on
NHE3 by Shank2 also has physiological implications. NHE3 is up- and
down-regulated as part of digestion, initially being inhibited and then
stimulated by various neurohormonal stimuli. In addition, the cAMP-
dependent inhibition is exaggerated in diarrheal disease (10). In this
regard, an interesting observation is that Shank2 inhibits the cAMP-
induced activation of cystic fibrosis transmembrane conductance regu-
lator, the major secretory transporter in the intestine and colon (16).
Therefore, the same protein, Shank2, regulates both absorptive and
secretory epithelial transporters in a reciprocal manner, and by using
this combinatorial activity Shank2 can effectively modulate net epithe-
lial transport.
Keeping the balance of and preventing overt cAMP signaling are
necessary for normal regulation of digestive physiology and for prevent-
ing severe diarrhea. It has been recognized that NHE3 exists in large
multiprotein complexes in size from 200 to 1200 kDa in intestinal tis-
sues (42). Maintaining and regulating a dynamic balance between
cAMP signal-conferring and -stopping complexes would be a critical
regulatorymechanism forNHE3 activity. All of the components that we
have discussed (NHE3, NHERF proteins, and Shank2 proteins) have
been shown to exist in renal proximal tubule cells by independent stud-
ies (7, 18). Therefore, we expect that a similar analogy may exist in the
kidney epithelia, although the present study did not explore the Shank2-
NHE3 interaction in kidney cells. Our findings about the role of Shank2
in the regulation of NHE3 activity and expression shed new light on the
mechanisms bywhich salt andwater transport are regulated tomaintain
systemic electrolyte, acid-base, and fluid volume homeostasis.
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